Is ACET or ACRS more undervalued in 2026?

CirclFi compares Adicet Bio, Inc. (ACET) and Aclaris Therapeutics, Inc. (ACRS) using 13 institutional-grade valuation models. ACET has a Quality of Company score of 5.1/10 while ACRS scores 7.1/10.

Which is a better buy — ACET or ACRS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ACET and ACRS valuations compare?

ACET at $8.64 and ACRS at $4.57 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ACET vs ACRS Valuation Comparison 2026 — Intrinsic Value Analysis

ACET

Biotechnology

Adicet Bio, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$8.64

Last close

Models

9/13

Active

ACRS

Biotechnology

Aclaris Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

LOW

Price

$4.57

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	ACET Fair Value	ACET Upside	ACRS Fair Value	ACRS Upside
Bayesian DCF	Intrinsic	$3.82	-55.8%	$1.33	-70.8%
Earnings Power Value	Intrinsic	—	—	$0.29	-93.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.04	-87.3%	$0.07	-98.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ACET vs ACRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ACET vs ACRS — Which Stock Is More Undervalued?

ACRS scores higher with a 7.1/10 quality rating vs ACET's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Adicet Bio, Inc. (ACET) and Aclaris Therapeutics, Inc. (ACRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ACET currently trades at $8.64 with a QOC of 5.1/10, while ACRS trades at $4.57 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).